Chong Kun Dang Pharmaceutical has filed a patent for a novel compound called donepezil ether palmitate, which is a modified form of the drug donepezil. This modified compound reduces the initial release of donepezil in the body, reducing the risk of side effects and allowing for a sustained release over a longer period of time. The patent claims the compound represented by Chemical Formula 1 or its pharmaceutically acceptable salt. GlobalData’s report on Chong Kun Dang Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Chong Kun Dang Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Chong Kun Dang Pharmaceutical's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Novel donepezil ether palmitate or a pharmaceutically acceptable salt
A recently filed patent (Publication Number: US20230303491A1) describes a compound and a pharmaceutical composition for preventing or treating dementia. The compound, represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof, is claimed to have potential therapeutic benefits for dementia. Additionally, a specific compound, represented by Chemical Formula 2 or a pharmaceutically acceptable salt thereof, is also mentioned in the patent.
The patent claims a sustained-release pharmaceutical composition for preventing or treating dementia, which includes either the compound represented by Chemical Formula 1 or the compound represented by Chemical Formula 2, or their respective pharmaceutically acceptable salts. This sustained-release composition is intended for injection and can be administered every 2 to 20 weeks. Alternatively, it can be administered via intramuscular injection.
The patent also discloses a method for preparing the compound represented by Chemical Formula 2. This method involves reacting donepezil free base with 2-(tetradecyloxy)acetyl chloride. Furthermore, the patent provides a detailed process for preparing the 2-(tetradecyloxy)acetyl chloride, which includes mixing 1-tetradecanol, sodium chloroacetate, and potassium hydroxide to obtain sodium 2-(tetradecyloxy)acetate. This compound is then reacted with an aqueous HCl solution to obtain 2-(tetradecyloxy)acetic acid, which is finally reacted with oxalyl chloride.
In summary, the patent describes a compound and a pharmaceutical composition that show potential for preventing or treating dementia. The sustained-release composition can be administered via injection every 2 to 20 weeks or via intramuscular injection. The patent also provides a method for preparing the compound and a detailed process for synthesizing a key intermediate compound. These findings may contribute to the development of new treatments for dementia.
To know more about GlobalData’s detailed insights on Chong Kun Dang Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
